Cargando…

Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease

In Pompe disease, the deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA) causes skeletal and cardiac muscle weakness, respiratory failure, and premature death. While enzyme replacement therapy using recombinant human GAA (rhGAA) can significantly improve patient outcomes, detailed disea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jason, Zhou, Chris J., Khodabukus, Alastair, Tran, Sabrina, Han, Sang-Oh, Carlson, Aaron L., Madden, Lauran, Kishnani, Priya S., Koeberl, Dwight D., Bursac, Nenad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100136/ https://www.ncbi.nlm.nih.gov/pubmed/33953320 http://dx.doi.org/10.1038/s42003-021-02059-4

Ejemplares similares

Engineering human pluripotent stem cells into a functional skeletal muscle tissue
por: Rao, Lingjun, et al.
Publicado: (2018)

Hydrostatic Isolated Limb Perfusion with Adeno-associated Virus Vectors Enhances Correction of Skeletal Muscle in Pompe Disease
por: Sun, Baodong, et al.
Publicado: (2010)

Tissue-Engineered Skeletal Muscle Models to Study Muscle Function, Plasticity, and Disease
por: Khodabukus, Alastair
Publicado: (2021)

Screening data from 19 patients with late‐onset Pompe disease for a phase I clinical trial of AAV8 vector‐mediated gene therapy
por: Hannah, William B., et al.
Publicado: (2023)

Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs
por: Madden, Lauran, et al.
Publicado: (2015)

Neuromuscular Development and Disease: Learning From in vitro and in vivo Models
por: Fralish, Zachary, et al.
Publicado: (2021)

Pompe disease- experience from South India
por: Lingappa, Lokesh, et al.
Publicado: (2013)

Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
por: Han, Sang-oh, et al.
Publicado: (2017)

Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction
por: Han, Sang-oh, et al.
Publicado: (2019)

Long term outcome and clinical experience on immune tolerance induction therapies in infantile Pompe disease
por: Austin, Stephanie, et al.
Publicado: (2013)

Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy
por: Prater, Sean N, et al.
Publicado: (2013)

Deficiency in MyD88 Signaling Results in Decreased Antibody Responses to an Adeno-Associated Virus Vector in Murine Pompe Disease
por: Zhang, Ping, et al.
Publicado: (2012)

Behavioral, social and school functioning in children with Pompe disease
por: Korlimarla, Aditi, et al.
Publicado: (2020)

Differential microRNA profiles of intramuscular and secreted extracellular vesicles in human tissue-engineered muscle
por: Vann, Christopher G, et al.
Publicado: (2022)

Assessment of toxicity and biodistribution of recombinant AAV8 vector–mediated immunomodulatory gene therapy in mice with Pompe disease
por: Wang, Gensheng, et al.
Publicado: (2014)

Corrigendum to “Assessment of toxicity and biodistribution of recombinant AAV8 vector–mediated immunomodulatory gene therapy in mice with Pompe disease”
por: Wang, Gensheng, et al.
Publicado: (2015)

Comparisons of Infant and Adult Mice Reveal Age Effects for Liver Depot Gene Therapy in Pompe Disease
por: Han, Sang-oh, et al.
Publicado: (2019)

Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease()
por: Chien, Yin-Hsiu, et al.
Publicado: (2017)

Pregnancy Outcomes in Late Onset Pompe Disease
por: Goker-Alpan, Ozlem, et al.
Publicado: (2020)

The Pompe Registry: tracking Pompe disease symptoms in a broad patient population
por: Byrne, B, et al.
Publicado: (2008)

Adenotonsillectomy should be avoided whenever possible in infantile-onset Pompe disease
por: Jones, Harrison N., et al.
Publicado: (2020)

Monitoring and Management of Respiratory Function in Pompe Disease: Current Perspectives
por: El Haddad, Léa, et al.
Publicado: (2023)

Clinical laboratory experience of blood CRIM testing in infantile Pompe disease
por: Bali, Deeksha S., et al.
Publicado: (2015)

Characterization of a canine model of glycogen storage disease type IIIa
por: Yi, Haiqing, et al.
Publicado: (2012)

Muscle ultrasound in patients with late-onset Pompe disease identified by newborn screening
por: Jackson, David G., et al.
Publicado: (2023)

Measurement Properties of 2 Novel PROs, the Pompe Disease Symptom Scale and Pompe Disease Impact Scale, in the COMET Study
por: Dimachkie, Mazen M., et al.
Publicado: (2023)

Dysregulation of Multiple Facets of Glycogen Metabolism in a Murine Model of Pompe Disease
por: Taylor, Kristin M., et al.
Publicado: (2013)

GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry
por: Reuser, Arnold J. J., et al.
Publicado: (2019)

Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy
por: Desai, Ankit K., et al.
Publicado: (2019)

Immune tolerance strategies in siblings with infantile Pompe disease — Advantages for a preemptive approach to high-sustained antibody titers
por: Stenger, Elizabeth O., et al.
Publicado: (2015)

Assessment of Dysphonia in Children with Pompe Disease Using Auditory-Perceptual and Acoustic/Physiologic Methods
por: Crisp, Kelly D., et al.
Publicado: (2021)

New Insights into Gastrointestinal Involvement in Late-Onset Pompe Disease: Lessons Learned from Bench and Bedside
por: Korlimarla, Aditi, et al.
Publicado: (2021)

Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease
por: De Groot, Anne S., et al.
Publicado: (2021)

Small-Fiber Neuropathy in Pompe Disease: First Reported Cases and Prospective Screening of a Clinic Cohort
por: Hobson-Webb, Lisa D., et al.
Publicado: (2015)

Meteorin-like is an injectable peptide that can enhance regeneration in aged muscle through immune-driven fibro/adipogenic progenitor signaling
por: Lee, David E., et al.
Publicado: (2022)

Pompe disease diagnosis and management guideline
por: Kishnani, Priya S., et al.
Publicado: (2006)

A Race Against Time—Changing the Natural History of CRIM Negative Infantile Pompe Disease
por: Gupta, Punita, et al.
Publicado: (2020)

Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort
por: Desai, Ankit K., et al.
Publicado: (2020)

The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients
por: Feeney, Erin J, et al.
Publicado: (2014)

Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid α-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease
por: Lim, Jeong-A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_84ide54jmuammd9t22tpl2e3tc